These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38160154)

  • 21. The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis.
    Hamura R; Haruki K; Taniai T; Yanagaki M; Shirai Y; Furukawa K; Usuba T; Fujioka S; Okamoto T; Nakabayashi Y; Uwagawa T; Ikegami T
    Int J Clin Oncol; 2022 Jul; 27(7):1188-1195. PubMed ID: 35426581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
    Ikezawa K; Kanai M; Ajiki T; Tsukamoto T; Toyokawa H; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
    J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):98-104. PubMed ID: 23798367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.
    Edeline J; Benabdelghani M; Bertaut A; Watelet J; Hammel P; Joly JP; Boudjema K; Fartoux L; Bouhier-Leporrier K; Jouve JL; Faroux R; Guerin-Meyer V; Kurtz JE; Assénat E; Seitz JF; Baumgaertner I; Tougeron D; de la Fouchardière C; Lombard-Bohas C; Boucher E; Stanbury T; Louvet C; Malka D; Phelip JM
    J Clin Oncol; 2019 Mar; 37(8):658-667. PubMed ID: 30707660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery.
    Akazawa Y; Mizuno S; Fujinami N; Suzuki T; Yoshioka Y; Ochiya T; Nakamoto Y; Nakatsura T
    Sci Rep; 2019 Apr; 9(1):5925. PubMed ID: 30976046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
    Katayose Y; Ohtsuka H; Kitamura Y; Masuda K; Nakagawa K; Yamamoto K; Yoshida H; Onogawa T; Motoi F; Naitoh T; Rikiyama T; Egawa S; Unno M
    Hepatogastroenterology; 2012 May; 59(115):691-5. PubMed ID: 22469710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
    Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
    Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer: A STROBE-compliant retrospective cohort study.
    Yin L; Xu Q; Li J; Wei Q; Ying J
    Medicine (Baltimore); 2018 Dec; 97(50):e13570. PubMed ID: 30558021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
    Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW
    Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone.
    Kagoura M; Kobayashi S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N
    Eur J Surg Oncol; 2024 Mar; 50(3):107980. PubMed ID: 38281442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
    Feng F; Cheng Q; Zhang D; Li B; Qin H; Xu C; Han M; Yu Y; Li Z; Li JY; Qiu Z; Xiong L; Liu C; Li F; Yi B; Jiang X
    Oncol Rep; 2020 Apr; 43(4):1089-1102. PubMed ID: 32323774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.
    Rizzo A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):547-554. PubMed ID: 33571059
    [No Abstract]   [Full Text] [Related]  

  • 33. A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
    Kobayashi S; Ikeda M; Nakachi K; Ueno M; Okusaka T; Todaka A; Satoi S; Tomokuni A; Konishi M; Furuse J
    Ann Surg Oncol; 2023 Nov; 30(12):7331-7337. PubMed ID: 37450093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.
    Kish M; Chan K; Perry K; Ko YJ
    Curr Oncol; 2020 Feb; 27(1):e20-e26. PubMed ID: 32218664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study.
    Lim KH; Oh DY; Chie EK; Jang JY; Im SA; Kim TY; Kim SW; Ha SW; Bang YJ
    BMC Cancer; 2009 Sep; 9():345. PubMed ID: 19781103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
    Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
    J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
    Primrose JN; Fox RP; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans JTR; Stocken D; Praseedom R; Ma YT; Davidson B; Neoptolemos JP; Iveson T; Raftery J; Zhu S; Cunningham D; Garden OJ; Stubbs C; Valle JW; Bridgewater J;
    Lancet Oncol; 2019 May; 20(5):663-673. PubMed ID: 30922733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation.
    Dee EC; Freret ME; Horick N; Raldow AC; Goyal L; Zhu AX; Parikh AR; Ryan DP; Clark JW; Allen JN; Ferrone CR; Fernandez-Del Castillo C; Tanabe KK; Drapek LC; Hong TS; Qadan M; Wo JY
    Ann Surg Oncol; 2020 Dec; 27(13):5161-5172. PubMed ID: 32740733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
    Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T;
    Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis.
    Miyata Y; Kogure R; Nakazawa A; Nagata R; Mitsui T; Ninomiya R; Komagome M; Maki A; Kawarabayashi N; Beck Y
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.